Abvc Biopharma annual operating income
2010
2011
2012
2013
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Abvc Biopharma Operating Income Growth & History (ABVC)
Abvc Biopharma's operating income was −$7.2M for fiscal 2025.
View full Abvc Biopharma company overviewAbvc Biopharma annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$7.2M | −$2.4M | — |
| 2024 | 2024-12-31 | −$4.7M | $2.1M | — |
| 2023 | 2023-12-31 | −$6.8M | $8.3M | — |
| 2022 | 2022-12-31 | −$15.1M | −$3.4M | — |
| 2021 | 2021-12-31 | −$11.7M | −$3.2M | — |
| 2020 | 2020-12-31 | −$8.5M | −$5.0M | — |
| 2019 | 2019-12-31 | −$3.5M | −$674,215 | — |
| 2018 | 2018-12-31 | −$2.8M | $1.4M | — |
| 2017 · Dec 31 | 2017-12-31 | −$4.1M | — | — |
| 2017 · Sep 30 | 2017-09-30 | −$4.0M | $7.0M | — |
| 2016 | 2016-09-30 | −$11.0M | — | — |
| 2013 | 2013-09-30 | −$177,259 | $965,787 | — |
| 2012 | 2012-09-30 | −$1.1M | $744,817 | — |
| 2011 | 2011-09-30 | −$1.9M | $1,610 | — |
| 2010 | 2010-09-30 | −$1.9M | — | — |
Abvc Biopharma quarterly operating income
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q4.15
Q1.16
Q2.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$779,526 | $1.5M | — |
| Q1 2026 | 2026-03-31 | −$1.6M | −$879,467 | — |
| Q4 2025 | 2025-12-31 | −$2.2M | −$1.5M | — |
| Q3 2025 | 2025-09-30 | −$2.0M | −$1.7M | — |
| Q2 2025 | 2025-06-30 | −$2.3M | −$1.4M | — |
| Q1 2025 | 2025-03-31 | −$693,005 | $2.1M | — |
| Q4 2024 | 2024-12-31 | −$704,564 | −$192,729 | — |
| Q3 2024 | 2024-09-30 | −$302,316 | $1.9M | — |
| Q2 2024 | 2024-06-30 | −$860,107 | $1.3M | — |
| Q1 2024 | 2024-03-31 | −$2.8M | −$932,071 | — |
| Q4 2023 | 2023-12-31 | −$511,835 | $2.6M | — |
| Q3 2023 | 2023-09-30 | −$2.2M | $1.6M | — |
| Q2 2023 | 2023-06-30 | −$2.2M | −$146,982 | — |
| Q1 2023 | 2023-03-31 | −$1.9M | $4.3M | — |
| Q4 2022 | 2022-12-31 | −$3.1M | $3.3M | — |
| Q3 2022 | 2022-09-30 | −$3.7M | −$1.7M | — |
| Q2 2022 | 2022-06-30 | −$2.0M | −$11,345 | — |
| Q1 2022 | 2022-03-31 | −$6.2M | −$5.0M | — |
| Q4 2021 | 2021-12-31 | −$6.4M | −$1.6M | — |
| Q3 2021 | 2021-09-30 | −$2.0M | −$680,788 | — |
| Q2 2021 | 2021-06-30 | −$2.0M | −$841,502 | — |
| Q1 2021 | 2021-03-31 | −$1.3M | −$81,368 | — |
| Q4 2020 | 2020-12-31 | −$4.9M | −$3.7M | — |
| Q3 2020 | 2020-09-30 | −$1.3M | −$174,144 | — |
| Q2 2020 | 2020-06-30 | −$1.2M | −$705,205 | — |
| Q1 2020 | 2020-03-31 | −$1.2M | −$440,811 | — |
| Q4 2019 | 2019-12-31 | −$1.1M | $65,865 | — |
| Q3 2019 | 2019-09-30 | −$1.1M | −$719,337 | — |
| Q2 2019 | 2019-06-30 | −$488,808 | $35,624 | — |
| Q1 2019 | 2019-03-31 | −$730,566 | −$56,367 | — |
| Q4 2018 | 2018-12-31 | −$1.2M | −$836,853 | — |
| Q3 2018 | 2018-09-30 | −$396,285 | $3.0M | — |
| Q2 2018 | 2018-06-30 | −$524,432 | −$334,953 | — |
| Q1 2018 | 2018-03-31 | −$674,199 | −$437,358 | — |
| Q4 2017 | 2017-12-31 | −$352,794 | −$142,408 | — |
| Q4 2017 · Sep 30 | 2017-09-30 | −$3.4M | −$2.8M | — |
| Q3 2017 | 2017-06-30 | −$189,479 | $99,619 | — |
| Q2 2017 | 2017-03-31 | −$236,841 | $6.4M | — |
| Q1 2017 | 2016-12-31 | −$210,386 | $3.3M | — |
| Q4 2016 | 2016-09-30 | −$597,828 | −$282,226 | — |
| Q2 2016 | 2016-06-30 | −$289,098 | −$287,598 | — |
| Q1 2016 | 2016-03-31 | −$6.6M | −$6.6M | — |
| Q4 2015 · Dec 31 | 2015-12-31 | −$3.5M | −$3.5M | — |
| Q4 2015 | 2015-09-30 | −$315,602 | — | — |
| Q3 2015 | 2015-06-30 | −$1,500 | −$1,470 | — |
| Q2 2015 | 2015-03-31 | $1,119 | $1,149 | — |
| Q1 2015 | 2014-12-31 | −$1,030 | −$1,020 | — |
| Q3 2014 | 2014-06-30 | −$30 | $19,343 | — |
| Q2 2014 | 2014-03-31 | −$30 | $20,422 | — |
| Q1 2014 | 2013-12-31 | −$10 | $137,424 | — |
| Q4 2013 | 2013-09-30 | $0 | $108,069 | — |
| Q3 2013 | 2013-06-30 | −$19,373 | $226,074 | — |
| Q2 2013 | 2013-03-31 | −$20,452 | $310,101 | — |
| Q1 2013 | 2012-12-31 | −$137,434 | $321,543 | — |
| Q4 2012 | 2012-09-30 | −$108,069 | $309,546 | — |
| Q3 2012 | 2012-06-30 | −$245,447 | $527,908 | — |
| Q2 2012 | 2012-03-31 | −$330,553 | −$1,837 | — |
| Q1 2012 | 2011-12-31 | −$458,977 | −$90,800 | — |
| Q4 2011 | 2011-09-30 | −$417,615 | — | — |
| Q3 2011 | 2011-06-30 | −$773,355 | −$434,456 | — |
| Q2 2011 | 2011-03-31 | −$328,716 | — | — |
| Q1 2011 | 2010-12-31 | −$368,177 | — | — |
| Q3 2010 | 2010-06-30 | −$338,899 | — | — |
Abvc Biopharma operating income trends
Over the last five fiscal years, Abvc Biopharma's operating income increased from −$8.5M to −$7.2M, a change of $1.4M. The latest reported quarter, Q2 2026, shows −$779,526.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Abvc Biopharma source filings ↗